| Primary |
| Thrombosis Prophylaxis |
17.6% |
| Drug Use For Unknown Indication |
17.1% |
| Anticoagulant Therapy |
10.5% |
| Deep Vein Thrombosis |
7.0% |
| Prophylaxis |
6.7% |
| Pulmonary Embolism |
5.2% |
| Product Used For Unknown Indication |
5.1% |
| Atrial Fibrillation |
4.1% |
| Haemodialysis |
3.6% |
| Coronary Artery Bypass |
3.1% |
| Thrombosis |
3.0% |
| Dialysis |
2.9% |
| Cardiac Operation |
2.8% |
| Myocardial Infarction |
2.0% |
| Intravenous Catheter Management |
1.9% |
| Percutaneous Coronary Intervention |
1.7% |
| Surgery |
1.7% |
| Acute Myocardial Infarction |
1.5% |
| Renal Failure Chronic |
1.5% |
| Catheterisation Cardiac |
1.0% |
|
| Heparin-induced Thrombocytopenia |
30.6% |
| Thrombocytopenia |
13.9% |
| Vomiting |
7.0% |
| Thrombosis |
5.5% |
| Syncope |
3.7% |
| Deep Vein Thrombosis |
3.6% |
| Platelet Count Decreased |
3.5% |
| Pharmaceutical Product Complaint |
3.4% |
| Thrombosis In Device |
3.3% |
| Hypotension |
3.0% |
| Pulmonary Embolism |
3.0% |
| Product Quality Issue |
2.7% |
| Haemorrhage |
2.5% |
| Nausea |
2.5% |
| Unresponsive To Stimuli |
2.4% |
| Therapeutic Product Contamination |
2.2% |
| Renal Failure |
1.8% |
| Shock |
1.8% |
| Haemoglobin Decreased |
1.8% |
| Retroperitoneal Haematoma |
1.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.2% |
| Product Used For Unknown Indication |
21.5% |
| Acute Myocardial Infarction |
6.5% |
| Anticoagulant Therapy |
5.9% |
| Thrombosis Prophylaxis |
5.6% |
| Myocardial Infarction |
5.3% |
| Pulmonary Embolism |
4.5% |
| Percutaneous Coronary Intervention |
4.4% |
| Deep Vein Thrombosis |
3.6% |
| Prophylaxis |
3.4% |
| Antiplatelet Therapy |
2.7% |
| Hypertension |
2.7% |
| Atrial Fibrillation |
2.5% |
| Acute Coronary Syndrome |
2.1% |
| Pain |
1.8% |
| Haemodialysis |
1.2% |
| Cardiac Failure |
1.1% |
| Angina Unstable |
1.1% |
| Thrombosis |
1.1% |
| Peripheral Ischaemia |
0.9% |
|
| Thrombocytopenia |
18.1% |
| Heparin-induced Thrombocytopenia |
9.7% |
| Vomiting |
8.8% |
| Death |
7.3% |
| Thrombosis |
5.2% |
| Thrombosis In Device |
4.7% |
| Pulmonary Embolism |
4.6% |
| Respiratory Failure |
3.9% |
| Haemorrhage |
3.6% |
| Platelet Count Decreased |
3.6% |
| Haemorrhage Intracranial |
3.5% |
| Myocardial Infarction |
3.4% |
| Drug Ineffective |
3.2% |
| Pneumonia |
3.1% |
| Shock Haemorrhagic |
3.1% |
| Vascular Pseudoaneurysm |
3.1% |
| Cerebral Haemorrhage |
3.0% |
| Gastrointestinal Haemorrhage |
2.8% |
| Retroperitoneal Haemorrhage |
2.7% |
| Premature Baby |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
45.6% |
| Drug Use For Unknown Indication |
12.2% |
| Prophylaxis |
6.9% |
| Coronary Artery Bypass |
5.9% |
| Hypertension |
3.9% |
| Acute Myocardial Infarction |
3.8% |
| Pain |
3.1% |
| Multiple Myeloma |
2.1% |
| Constipation |
1.8% |
| Infection Prophylaxis |
1.7% |
| Aortic Valve Replacement |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Myocardial Infarction |
1.3% |
| Acute Coronary Syndrome |
1.3% |
| Premedication |
1.3% |
| Catheterisation Cardiac |
1.2% |
| Diabetes Mellitus |
1.2% |
| Anticoagulant Therapy |
1.2% |
| Nausea |
1.2% |
| Mitral Valve Replacement |
1.0% |
|
| Pain |
10.1% |
| Injury |
9.7% |
| Unevaluable Event |
8.3% |
| Fear |
6.4% |
| Renal Failure |
6.0% |
| Anxiety |
5.8% |
| Thrombocytopenia |
5.7% |
| Vomiting |
5.7% |
| Anhedonia |
5.4% |
| Death |
4.4% |
| Emotional Distress |
4.1% |
| Renal Failure Acute |
3.9% |
| Renal Impairment |
3.6% |
| Stress |
3.4% |
| Pulmonary Embolism |
3.4% |
| Depression |
3.2% |
| Sepsis |
3.0% |
| Pyrexia |
2.7% |
| Renal Injury |
2.6% |
| Weight Decreased |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
27.6% |
| Acute Myocardial Infarction |
18.2% |
| Hypertension |
8.4% |
| Drug Use For Unknown Indication |
8.0% |
| Acute Coronary Syndrome |
5.3% |
| Myocardial Infarction |
5.3% |
| Osteoporosis |
3.6% |
| Infection Prophylaxis |
2.7% |
| Anticoagulant Therapy |
2.2% |
| Atrial Fibrillation |
2.2% |
| Abdominal Discomfort |
1.8% |
| Abdominal Pain |
1.8% |
| Anxiety |
1.8% |
| Chest Pain |
1.8% |
| Constipation |
1.8% |
| Percutaneous Coronary Intervention |
1.8% |
| Prophylaxis |
1.8% |
| Colon Cancer |
1.3% |
| Coronary Artery Thrombosis |
1.3% |
| Enteral Nutrition |
1.3% |
|
| Drug Interaction |
22.5% |
| Vascular Pseudoaneurysm |
10.0% |
| Multi-organ Failure |
7.5% |
| Oesophageal Rupture |
7.5% |
| Post Procedural Haemorrhage |
7.5% |
| Gastrointestinal Haemorrhage |
5.0% |
| Increased Tendency To Bruise |
5.0% |
| Tachycardia |
5.0% |
| Thrombocytopenia |
5.0% |
| Cerebral Haemorrhage |
2.5% |
| Coagulopathy |
2.5% |
| Hepatic Function Abnormal |
2.5% |
| International Normalised Ratio Abnormal |
2.5% |
| Pulmonary Haemorrhage |
2.5% |
| Shock Haemorrhagic |
2.5% |
| Small Intestinal Resection |
2.5% |
| Thrombosis |
2.5% |
| Toxicity To Various Agents |
2.5% |
| Upper Gastrointestinal Haemorrhage |
2.5% |
|
